What are the overview, complications, and treatment of Guillain‑Barré syndrome?

Guillain-Barré Syndrome: Overview, Complications, and Treatment

Overview

Guillain-Barré syndrome (GBS) is an acute-onset, immune-mediated polyradiculoneuropathy that represents the leading global cause of acquired neuromuscular paralysis, typically triggered by preceding infections. 1 The disease manifests as progressive ascending weakness with diminished or absent reflexes, reaching maximum disability within 2 weeks in most patients 1. Up to 22% of patients require mechanical ventilation, and mortality ranges from 3-10% even with optimal care 1.

Clinical Presentation

The classic presentation involves:

• Progressive motor weakness beginning in the legs and advancing proximally
• Sensory symptoms including paresthesias and pain (present in >50% of patients) 1
• Autonomic dysfunction in two-thirds of patients, manifesting as cardiac arrhythmias, blood pressure instability, or urinary retention 1
• Bulbar and facial weakness affecting swallowing and facial expression 1

Disease Course

GBS follows a monophasic pattern with three distinct phases 1:

1. Progressive phase: Rapid deterioration over days to 2 weeks
2. Plateau phase: Stabilization lasting days to weeks
3. Recovery phase: Gradual improvement, with 60-80% achieving independent ambulation by 6 months 1

Critical insight: Up to two-thirds of deaths occur during the recovery phase, primarily from cardiovascular and respiratory complications 1. This demands continued vigilance even after apparent stabilization.

---

Complications

Life-Threatening Complications

Respiratory failure is the most critical acute complication:

• Occurs in 20-22% of patients 1
• Use the "20/30/40 rule" for risk assessment: vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O indicates imminent respiratory failure 1
• Single breath count ≤19 predicts need for mechanical ventilation 1
• The Erasmus GBS Respiratory Insufficiency Score (EGRIS) calculates probability (1-90%) of requiring ventilation within 1 week 1

Cardiovascular complications 1:

• Cardiac arrhythmias
• Marked blood pressure fluctuations
• These complications persist into recovery phase and require ongoing monitoring

GBS-Specific Complications

Neurological complications 1:

• Bulbar palsy: Inability to swallow safely, requiring enteral nutrition
• Corneal ulceration: From facial palsy and inability to close eyes
• Limb contractures, ossification, and pressure palsies: From prolonged immobility

Frequently Overlooked Complications

Psychological and pain syndromes 1:

• Pain affects >50% of patients
• Hallucinations, anxiety, and depression are frequent
• Critical caveat: Patients with complete paralysis maintain intact consciousness, vision, and hearing—be mindful of bedside conversations 1

Standard Hospital Complications

Apply standard preventive measures for 1:

• Pressure ulcers
• Hospital-acquired infections (pneumonia, UTIs)
• Deep vein thrombosis

Long-Term Complications

Residual disability affects 20-40% of patients 1:

• Incomplete motor and sensory recovery
• Fatigue (60-80% of patients)—often the most disabling long-term complaint 1
• Neuropathic pain
• Psychological distress

---

Treatment

Primary Immunotherapy

IVIg is the preferred first-line treatment for GBS, administered as 0.4 g/kg body weight daily for 5 days (total 2 g/kg). 1 This recommendation is based on equal efficacy to plasma exchange but superior ease of administration and wider availability.

Plasma exchange (200-250 ml plasma/kg body weight in five sessions) is equally effective but more difficult to administer 1. Consider plasma exchange when:

• IVIg is contraindicated or unavailable
• Patient has IgA deficiency (relative contraindication to IVIg)

What NOT to Use

Corticosteroids are contraindicated 1:

• Eight randomized controlled trials showed no benefit
• Oral corticosteroids demonstrated negative effects on outcome
• Combination therapy (plasma exchange followed by IVIg) is no more effective than either alone 1

Special Populations

Pregnant women 1:

• Neither IVIg nor plasma exchange is contraindicated
• IVIg is preferred due to simpler monitoring requirements

Children 1:

• Use standard adult dosing (0.4 g/kg daily × 5 days)
• Avoid 2-day regimens (2 g/kg over 2 days)—associated with higher treatment-related fluctuation rates (5/23 vs 0/23) 1

GBS variants 1:

• Miller Fisher Syndrome (MFS): Generally no treatment needed; monitor closely for progression
• Bickerstaff brainstem encephalitis (BBE): Treat with IVIg or plasma exchange

Managing Treatment Failure

Treatment-related fluctuations (TRFs) occur in 6-10% of patients 1:

• Defined as deterioration within 2 months after initial improvement
• Repeat full course of IVIg or plasma exchange is common practice, though evidence is limited 1

Insufficient response (40% of patients show no improvement in first 4 weeks) 1:

• Does not mean treatment was ineffective
• Consider repeating treatment, but no evidence supports improved outcomes 1
• Distinguish from acute-onset CIDP (≥3 TRFs or deterioration ≥8 weeks after onset) 1

---

Monitoring Algorithm

Respiratory Monitoring (All Patients)

Assess every 4-6 hours in progressive phase 1:

1. Single breath count (abnormal if ≤19)
2. Vital capacity (risk if <20 ml/kg)
3. Maximum inspiratory pressure (risk if <30 cmH₂O)
4. Maximum expiratory pressure (risk if <40 cmH₂O)
5. Use of accessory respiratory muscles

ICU Admission Criteria 1

Transfer immediately if any of:

• Evolving respiratory distress with vital capacity <15-20 ml/kg
• Severe autonomic dysfunction (arrhythmias, marked BP variation)
• Severe bulbar dysfunction or diminished cough reflex
• Rapid progression of weakness
• EGRIS score indicating high probability of ventilation need

Neurological Monitoring 1

• Muscle strength: Medical Research Council grading scale
• Functional disability: GBS disability scale
• Swallowing and cough: Assess regularly
• Autonomic function: ECG, heart rate, blood pressure, bowel/bladder function

Recovery Phase Monitoring

Maintain vigilance during recovery—two-thirds of deaths occur in this phase 1:

• Monitor for arrhythmias
• Watch for blood pressure shifts
• Assess for respiratory distress from mucus plugs
• Especially critical in patients recently discharged from ICU or with cardiovascular risk factors

---

Multidisciplinary Management

Optimal outcomes require a multidisciplinary team 1:

• Nurses (pressure ulcer prevention, autonomic monitoring)
• Physiotherapists (range-of-motion exercises, strength training)
• Occupational therapists (activities of daily living)
• Speech therapists (swallowing assessment)
• Dietitians (nutritional support)
• Rehabilitation specialists (coordinated recovery programs)

Pain Management

Address pain aggressively as it affects >50% of patients 1:

• NSAIDs for mild pain
• Carbamazepine or gabapentin for neuropathic pain
• Recognize and treat psychological symptoms early

Rehabilitation

Exercise programs improve outcomes 1:

• Range-of-motion exercises
• Stationary cycling
• Walking and strength training
• Monitor intensity closely—overwork causes fatigue

Recovery continues beyond 6 months: Improvement can occur >5 years after onset 1. Set realistic expectations while maintaining optimism about long-term recovery potential.